This Article Full Text Full Text (PDF) Supplemental Data All Versions of this Article: 148/3/1330    most recent Author Manuscript (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Patel, O. Articles by Baldwin, G. S. Search for Related Content PubMed PubMed Citation Articles by Patel, O. Articles by Baldwin, G. S.

C-Terminal Fragments of the Gastrin-Releasing Peptide Precursor Stimulate Cell Proliferation via a Novel Receptor

Department of Surgery, University of Melbourne, Austin Health, Heidelberg, Victoria 3084, Australia

Address all correspondence and requests for reprints to: Graham S. Baldwin, Department of Surgery, Austin Health, Studley Road, Heidelberg, Victoria 3084, Australia. E-mail: grahamsb{at}unimelb.edu.au.

There are many precedents for the production from a single precursor of multiple peptides, with independent receptors and different bioactivities. Gastrin-releasing peptide (GRP) is initially synthesized as amino acids 1–27 of a 125-residue precursor, proGRP, and is subsequently cleaved and amidated to form GRP18–27. We investigated the hypothesis that C-terminal proGRP peptides are also biologically active. Human proGRP18–125 was expressed in Escherichia coli as a glutathione S-transferase fusion protein. Recombinant proGRP18–125 stimulated proliferation and migration of the human colorectal carcinoma cell line DLD-1. The observations that an antagonist selective for the GRP receptor did not inhibit activity in either proliferation or migration assays and that the recombinant peptide did not bind to either the GRP receptor or orphan receptor BRS-3 indicated that neither activity was mediated by the known GRP receptors. Recombinant human proGRP31–125 and proGRP42–98 were also prepared and shown to stimulate proliferation of DLD-1 cells and the human prostate carcinoma cell line DU145. The synthetic peptides proGRP47–68 and [Tyr79]proGRP80–97 stimulated inositol phosphate production, MAPK kinase activity, and proliferation and migration of DLD-1 cells. Binding sites for both radioiodinated synthetic peptides were demonstrated on DLD-1 cells. Each peptide was able to compete with the other for binding, and a GRP receptor antagonist did not inhibit binding of either peptide. We conclude that peptides derived from the C terminus of proGRP are biologically active and that their activity is mediated by a receptor distinct from the two known GRP receptors.

This article has been cited by other articles:

				R. T. Jensen, J. F. Battey, E. R. Spindel, and R. V. Benya International Union of Pharmacology. LXVIII. Mammalian Bombesin Receptors: Nomenclature, Distribution, Pharmacology, Signaling, and Functions in Normal and Disease States Pharmacol. Rev., March 1, 2008; 60(1): 1 - 42. [Abstract] [Full Text] [PDF]